Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VOR | PRESS-RELEASE | neutral | 3/10 | Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), a | Aug 11, 2026 |
| VTAK | PRESS-RELEASE | neutral | 2/10 | Catheter Precision subsidiary Flyte announced a strategic partnership with The Nucleus Network to sponsor its inaugural | Aug 11, 2026 |
| MREO | PRESS-RELEASE | neutral | 4/10 | Mereo BioPharma reported Q2 2026 results with zero revenue and a net loss of $7.0M, in line with consensus EPS of -$0.01 | Aug 11, 2026 |
| SGMT | PRESS-RELEASE | neutral | 5/10 | Sagimet Biosciences reported Q2 2026 net loss of $14.0 million ($0.26 per share), wider than the $10.4 million loss in Q | Aug 11, 2026 |
| STIM | PRESS-RELEASE | bullish | 6/10 | Neuronetics reported Q2 2026 revenue of $41.6M (+9.1% YoY), beating the $40.2M consensus, and EPS of -$0.05, a 59.2% bea | Aug 11, 2026 |
| BCAX | PRESS-RELEASE | mixed | 6/10 | Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensu | Aug 11, 2026 |
| TARA | PRESS-RELEASE | neutral | 4/10 | Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven b | Aug 11, 2026 |
| TONX | PRESS-RELEASE | bullish | 6/10 | TON Strategy reported Q2 2026 results with $15.0M in Gram staking revenue (up from $3.0M in Q1), driven by the TON netwo | Aug 11, 2026 |
| KLRS | PRESS-RELEASE | neutral | 4/10 | Kalaris Therapeutics reported Q2 2026 EPS of -$0.48, a 7.1% beat vs consensus of -$0.49, but net loss widened slightly t | Aug 11, 2026 |
| TOVX | PRESS-RELEASE | neutral | 5/10 | Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07 per share) vs $13.1M ($1.93 per sha | Aug 11, 2026 |
| LBRX | PRESS-RELEASE | bullish | 7/10 | LB Pharmaceuticals reported Q2 2026 net loss of $51.6M ($1.71/share) vs $4.9M a year ago, reflecting heavy R&D investmen | Aug 11, 2026 |
| BSIN | PRESS-RELEASE | neutral | 4/10 | Big Sky Industrial reported Q2 2026 revenue of $2.1M, essentially flat YoY, and a net loss of $2.3M ($0.04 per share), n | Aug 11, 2026 |
| DOMH | PRESS-RELEASE | bearish | 6/10 | Dominari Holdings reported Q2 2026 revenue of $16.8M, down 57% YoY from $38.9M, driven by a sharp decline in underwritin | Aug 11, 2026 |
| LAR | PRESS-RELEASE | bearish | 6/10 | Lithium Argentina reported Q2 2026 EPS of $0.01, a 94.9% miss vs the $0.20 consensus, on zero revenue (pre-revenue corpo | Aug 11, 2026 |
| AURA | PRESS-RELEASE | bearish | 6/10 | Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0. The net loss w | Aug 11, 2026 |
| CALC | PRESS-RELEASE | neutral | 4/10 | CalciMedica reported Q2 2026 financial results with a net loss of $7.7M ($0.45/share) vs $6.0M ($0.40/share) in Q2 2025, | Aug 11, 2026 |
| PRLD | PRESS-RELEASE | bullish | 5/10 | Prelude Therapeutics reported Q2 2026 EPS of -$0.14, beating consensus of -$0.18 by 22.2%, and generated $5.7M in revenu | Aug 11, 2026 |
| GANX | PRESS-RELEASE | bullish | 6/10 | Gain Therapeutics reported Q2 2026 EPS of -$0.11, beating consensus of -$0.15 by 26.7%, with net loss narrowing to $4.7M | Aug 11, 2026 |
| TNGX | PRESS-RELEASE | bullish | 7/10 | Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zer | Aug 11, 2026 |
| ACIU | PRESS-RELEASE | bullish | 7/10 | AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunot | Aug 11, 2026 |
| BMM | PRESS-RELEASE | mixed | 6/10 | Blue Moon Metals announced the acquisition of 33 tungsten and antimony projects in the western U.S. for ~US$15.5M in sto | Aug 11, 2026 |
| CDNL | PRESS-RELEASE | mixed | 6/10 | Cardinal Infrastructure Group reported record Q2 2026 revenue of $226.9M (+114% YoY, +64% organic), raised full-year rev | Aug 11, 2026 |
| STTK | PRESS-RELEASE | neutral | 5/10 | Shattuck Labs reported Q2 2026 net loss of $0.12 per share, in line with consensus of -$0.12, with no revenue. The key p | Aug 11, 2026 |
| UCL | PRESS-RELEASE | neutral | 1/10 | uCloudlink Group Inc. announced it will report its Q2 2026 results on August 18, 2026. | Aug 11, 2026 |
| BEKE | PRESS-RELEASE | neutral | 1/10 | KE Holdings Inc. announced it will report its Q2 2026 results on August 21, 2026. | Aug 11, 2026 |
| THCH | PRESS-RELEASE | neutral | 1/10 | TH International Limited announced it will report its Q2 2026 results on August 18, 2026. | Aug 11, 2026 |
| UCL | PRESS-RELEASE | bearish | 6/10 | UCLOUDLINK Group received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 33 consecutiv | Aug 11, 2026 |
| FLX | PRESS-RELEASE | neutral | 1/10 | BingEx Limited announced it will report its Q2 2026 results on August 20, 2026. | Aug 11, 2026 |
| SFD | PRESS-RELEASE | bearish | 6/10 | Smithfield Foods reported Q2 FY2026 EPS of $0.60 (GAAP) vs. $0.60 consensus, in line with expectations, and net sales of | Aug 11, 2026 |
| LI | PRESS-RELEASE | neutral | 1/10 | Li Auto Inc. announced it will report its Q2 2026 results on August 26, 2026. | Aug 11, 2026 |